Novo Nordisk A/S (NYSE:NVO) Shares Sold by Beacon Capital Management LLC

Beacon Capital Management LLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,463 shares of the company’s stock after selling 136 shares during the quarter. Beacon Capital Management LLC’s holdings in Novo Nordisk A/S were worth $212,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in NVO. International Assets Investment Management LLC lifted its stake in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. Mediolanum International Funds Ltd bought a new position in shares of Novo Nordisk A/S in the third quarter valued at $98,765,000. DAVENPORT & Co LLC increased its holdings in shares of Novo Nordisk A/S by 75.1% in the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after buying an additional 451,641 shares in the last quarter. Wellington Management Group LLP acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $42,017,000. Finally, World Investment Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 2,655.9% in the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock worth $33,388,000 after acquiring an additional 270,234 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $77.94 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.75. The firm has a market capitalization of $349.75 billion, a price-to-earnings ratio of 23.69, a price-to-earnings-growth ratio of 0.96 and a beta of 0.45. The company has a 50 day simple moving average of $88.65 and a 200-day simple moving average of $109.83. Novo Nordisk A/S has a 52-week low of $77.82 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts predict that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 21.88%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.